BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan
Shots:
- The P-III (KarMMa-3) trial investigates Abecma vs standard therapies for RRMM in patients (n=386) with two to four prior lines of treatment, incl. immunomodulatory agents, proteasome inhibitors, and daratumumab & were refractory to the last treatment regimen
- The approval was based on the P-III (KarMMa-3) study, revealing mPFS of 13.3mos. vs 4.4mos. & ORR of 71.3% vs 41.7% in Abecma and standard therapies with a 51% reduction in the risk of disease progression or death
- Abecma is a BCMA-directed CAR T cell immunotx. that targets BCMA on multiple myeloma cells to induce CAR T cell proliferation and cytokine release, leading to the destruction of BCMA-expressing cells
Ref: BMS | Image: BMS
Related News:- BMS & 2seventy Bio Announces the US FDA Review of sBLA for Abecma to treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
